Shares of Corbus Pharmaceuticals have raced 325% higher in 2016 due to its Resunab drug which received “Fast Track” designation by the Food and Drug Administration. The company’s CEO Dr. Yuval Cohen does not expect things to slow down anytime soon.
Subscribe to TheStreetTV on YouTube:
For more content from TheStreet visit:
Check out all our videos:
Follow TheStreet on Twitter:
Like TheStreet on Facebook:
Follow TheStreet on LinkedIn:
Follow TheStreet on Google+:
source
